The Weekly Litigation News Digest is now live. Subscribe now

Sandoz competitive analysis

Loading summary...

Explore patent oppositions filed by Sandoz against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Iron Complex Compounds For Therapeutic UsePHARMACOSMOS HOLDINGOct 1, 2025
Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIMSep 18, 2025
Methods Of Treating Prostate CancerJANSSEN PHARMACEUTICASep 17, 2025
Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-OlateGILEAD SCIENCESSep 3, 2025
Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry DiseaseAMICUS THERAPEUTICSSep 3, 2025
Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry DiseaseAMICUS THERAPEUTICSAug 13, 2025
Treatment Of Prostate CancerMYOVANT SCIENCESAug 7, 2025
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALSJul 15, 2025
Methods For Dose Initiation Of Aripiprazole TreatmentsOTSUKA PHARMACEUTICALJul 4, 2025
Methods Of Treating Pulmonary Arterial HypertensionACTELION PHARMACEUTICALSJun 4, 2025

Explore Sandoz's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
Dec 4, 2024An Inhaler Device1
Jun 1, 2022Storage Stable Composition Comprising Rifaximin Alpha1
Dec 22, 2021Storage Stable Composition Comprising Rifaximin Alpha1
Jul 7, 2021Pharmaceutical Composition Containing Rifaximin Alpha & Delta3
Sep 23, 2020Crystalline Eravacycline Bis-Hydrochloride1
Apr 22, 2020Oral Dosage Form Comprising Rifaximin In Form Beta1
Jan 22, 2020Crystalline Dapagliflozin Hydrate1
May 29, 2019Quantification Of Misfolded Tnfr2:Fc1
May 8, 2019Polymorphs Of Febuxostat1
Mar 27, 2019Pharmaceutical Composition Containing Crystalline Macitentan1

Latest PTAB cases involving Sandoz

Discover the latest PTAB cases involving Sandoz, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 15, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Sandoz

IPR2023-00478Feb 3, 2023SANDOZACERTA PHARMAInstitution Denied
PGR2022-00054Jul 29, 2022SANDOZBIOGEN MAInstitution Denied
PGR2022-00037May 2, 2022SANDOZBOEHRINGER INGELHEIMInstitution Denied
IPR2019-00865Mar 21, 2019SANDOZPHARMACYCLICSFinal Written Decision
IPR2018-00156Nov 6, 2017SANDOZABBVIE BIOTECHNOLOGYInstitution Denied
IPR2018-00002Oct 2, 2017SANDOZABBVIE BIOTECHNOLOGYInstitution Denied
IPR2017-02105Sep 14, 2017SANDOZABBVIE BIOTECHNOLOGYTerminated-Settled
IPR2017-02106Sep 14, 2017SANDOZABBVIE BIOTECHNOLOGYTerminated-Settled
IPR2017-02036Aug 31, 2017SANDOZGENENTECHInstitution Denied
IPR2017-02042Aug 31, 2017SANDOZGENENTECHInstitution Denied

Peer Comparison New

IP litigation analysis comparing Sandoz with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
SANDOZ1191619 -
ABBVIE BIOTECHNOLOGY - - - 22
BOEHRINGER INGELHEIM314221
NOVO NORDISK810519